In search of the ideal immunopanel to distinguish metastatic mammary carcinoma from primary lung carcinoma: A tissue microarray study of 207 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 4, 2014, Pages 266-274

  Kawaguchi, Kathy R ^a   Lu, Fang I ^b   Kaplan, Rachel ^a   Liu, Yi Fang ^a   Chadwick, Paul ^a   Chen, Zhengming ^a   Brogi, Edi ^b   Shin, Sandra J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

carcinoma; GATA 3; metastatic breast versus lung; Napsin A; TTF 1

Indexed keywords

ANDROGEN RECEPTOR; CASEIN; CYTOKERATIN 20; CYTOKERATIN 7; ESTROGEN RECEPTOR; MAMMAGLOBIN; NAPSIN A; PROGESTERONE RECEPTOR; PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; DNA BINDING PROTEIN; GATA3 PROTEIN, HUMAN; NAPSA PROTEIN, HUMAN; TTF1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; COLLOID CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SARCOMATOID CARCINOMA; TISSUE MICROARRAY; BREAST; BREAST NEOPLASMS; CARCINOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY;

ASPARTIC ACID ENDOPEPTIDASES; BREAST; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM METASTASIS; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898540037     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318297cc0b     Document Type: Article

References (53)

1. Kamby C, Andersen J, Ejlertsen B, et al. Pattern of spread and progression in relation to the characteristics of the primary tumour in human breast cancer. Acta Oncol. 1991;30:301-308.
2. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624-1633.
3. Porter GJ, Evans AJ, Pinder SE, et al. Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clin Radiol. 2004;59:1094-1098.
4. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-2366.
5. Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994;73:1615-1620.
6. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:406-414.
7. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26:392-398.
8. Casey JJ, Stempel BG, Scanlon EF, et al. The solitary pulmonary nodule in the patient with breast cancer. Surgery. 1984;96:801-805.
9. Okasaka T, Usami N, Mitsudomi T, et al. Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. J Surg Oncol. 2008;98:510-514.
10. Kitada M, Sato K, Matsuda Y, et al. Role of treatment for solitary pulmonary nodule in breast cancer patients. World J Surg Oncol. 2011;9:124.
11. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratin-7 and cytokeratin-20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
12. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008;132:239-243.
13. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.
14. Glass C, Fuchs E. Isolation, sequence, and differential expression of a human K7 gene in simple epithelial cells. J Cell Biol. 1988;107: 1337-1350.
15. Moll R, Schiller DL, Franke WW. Identification of protein-it of the intestinal cytoskeleton as a novel type-I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
16. Green S, Walter P, Kumar V, et al. Human estrogen-receptor CDNA - sequence, expression and homology to V-Erb-A. Nature. 1986;320:134-139.
17. Guiochon-Mantel A, Loosfelt H, Lescop P, et al. Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers. Cell. 1989;57:1147-1154.
18. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13:1558-1568.
19. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
20. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. AmJ Clin Pathol. 2005;123:21-27.
21. Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009;17:393-402.
22. Gomez-Fernandez C, Mejias A, Walker G, et al. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem MolMorphol. 2010;18:137-141.
23. Dabbs DJ, Landreneau RJ, Liu YL, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405.
24. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol. 2006;14:83-87.
25. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996;56:860-865.
26. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20:208-214.
27. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113.
28. Yan Z, Gidley J, Horton D, et al. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol. 2009;37:475-478.
29. Wang Z, Spaulding B, Sienko A, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol. 2009;2:384-389.
30. Albergaria A, Paredes J, Sousa B, et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009;11:R40.
31. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 2003;98:703-711.
32. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725-731.
33. Usary J, Llaca V, Karaca G, et al. Mutation of GATA3 in human breast tumors. Oncogene. 2004;23:7669-7678.
34. Kouros-Mehr H, Slorach EM, Sternlicht MD, et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006;127:1041-1055.
35. Hoch RV, Thompson DA, Baker RJ, et al. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999;84:122-128.
36. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev. 2008;17:365-373.
37. Ciocca V, Daskalakis C, Ciocca RM, et al. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol. 2009;40:489-495.
38. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
39. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25:2273-2284.
40. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J Steroid Biochem Mol Biol. 1996;56(1-6 Spec No):113-117.
41. Toth-Fejel S, Cheek J, Calhoun K, et al. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg. 2004;139:50-54.
42. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, et al. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer. 1992;52:581-584.
43. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008;8:149.
44. Collins LC, Cole KS,Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24:924-931.
45. Rades D, Setter C, Dahl O, et al. The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 2012;118:157-163.
46. Shidham VB, Komorowski RA, Machhi JK. Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol. 2006;1:34.
47. Bingle CD. Thyroid transcription factor-1. Int J Biochem Cell Biol. 1997;29:1471-1473.
48. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol. 2012;20:429-444.
49. Schauer-Vukasinovic V, Bur D, Kling D, et al. Human napsin A: expression, immunochemical detection, and tissue localization. FEBS Lett. 1999;462:135-139.
50. Ordonez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol. 2012;19:66-73.
51. Bishop JA, Sharma R, Illei PB, et al. and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
52. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011;19:313-317.
53. Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol. 2010; 34:1881-1885.